Anti-CD20 therapies, a type of MS treatment, changes levels and profiles of several immune cells in people with MS, a study ...

ATOM is now well poised to continue to the upside as trading volume tripled over the past 24 hours, indicating optimism from ...

CD20, a transmembrane calcium channel required for B cell activation, proliferation, and differentiation, has emerged as a key therapeutic target for B-cell malignancies and autoimmune disorders ...

CD20 expression levels were associated with patient outcomes following treatment with bispecific CD20xCD3 antibodies in patients with B-cell lymphomas in a new study. The findings, which were ...

TG Therapeutics sees growth from BRIUMVI’s MS launch, but competition, pipeline risks, and valuation concerns limit upside.

Alternative splicing of its 5′-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies. Blood, 2023; 142 (20): 1724 DOI: 10.1182/blood.2023020400; ...

The review concludes that CD20-targeted chimeric antigen receptor (CAR) T-cell therapy is an option worth exploring, despite potential safety concerns that warrant more extensive research.

“Anti-CD20 Monoclonal Antibodies Market” from 2024-2034 with covered segments (By Product Type (First Generation Anti-CD20 Monoclonal Antibodies, Second Generation Anti-CD20 Monoclonal ...

While the CD20 is down over 3% in the last 24-hour period, tokens including PAXG and XAUT are up 0.7% to over $3,100. These tokens are up more than 18% year-to-date, while BTC is down 12.5% and ...

Arthritis & Rheumatism. 2008;58(6):1566-1575. B cells, precursors of autoantibody-secreting cells, have emerged as promising new therapeutic targets in autoimmune diseases, including ...

In patients with myasthenia gravis (MG) who had anti-acetylcholine receptor antibodies or anti-muscle-specific kinase ...

Allogeneic BCMA or dual-targeting CD19/CD20 CAR-T cells developed using this platform exhibit robust antitumor activity in the presence of NK cells, indicating that THANK-u Plus™ has broad ...